{"id":9605,"date":"2004-07-29T00:36:44","date_gmt":"2004-07-29T00:36:44","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=9605"},"modified":"2014-05-22T16:59:04","modified_gmt":"2014-05-22T16:59:04","slug":"guidelines-for-t-20","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/9605","title":{"rendered":"Guidelines for T-20"},"content":{"rendered":"<p><strong>Guidelines for using T-20, (enfuvirtide, Fuzeon), have been produced by an international panel of experienced clinicians following a Roche-sponsored roundtable meeting and were published in 21 May issue of AIDS. They provide in greater detail a similar approach to that recommended in the British HIV Association (BHIVA) Guidelines.<\/strong><\/p>\n<p>The guidelines address:<\/p>\n<ul>\n<li>Use of resistance history and testing to optimise background therapy<\/li>\n<li>Optimal and less-than-optimal uses of T-20<\/li>\n<li>Safety and toxicity: injection site reactions, pneumonia and hypersensitivity<\/li>\n<li>Importance of training and support from healthcare professionals to assistant patients in successfully introducing T-20 into their daily routines<\/li>\n<li>Investment in patient training programmes to yield significant returns in the maintenance of adherence, patient confidence, and in the benefit of T-20 therapy.<\/li>\n<\/ul>\n<p>The full guidelines are only available online to subscribers or as a pay-to-view article but reprint copies are available free from the Roche Drug Information Department on 0800 328 1629.<\/p>\n<h3>Comment<\/h3>\n<p><strong>The changes to the expanded access programme for tipranavir (see earlier article) should mean that patients waiting to use T-20 with additional active drugs, now have a more supportive regimen.<\/strong><\/p>\n<p><strong>Guidelines for using T-20 in London have been produced by the London Drugs Advisory Group of the HIV Commissioners Consortium, and this is posted to the BIVA website:<br \/>\n<\/strong><a href=\"http:\/\/www.bhiva.org\/consortium\/t20.html\">http:\/\/www.bhiva.org\/consortium\/t20.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Guidelines for using T-20, (enfuvirtide, Fuzeon), have been produced by an international panel of experienced clinicians following a Roche-sponsored roundtable meeting and were published in 21 May issue of AIDS. They provide in greater detail a similar approach to that &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-9605","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=9605"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/9605\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=9605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=9605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=9605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}